General control nondepressible 5 (GCN5), the first identified transcription-related lysine acetyltransferase (KAT), is an important catalytic component of a transcriptional regulatory SAGA (Spt-Ada-GCN5-Acetyltransferase) and ATAC (ADA2A-containing) complex. While GCN5 has been implicated in cancer development, its role in cervical cancer is not known. The human papillomavirus (HPV) oncoprotein E7 abrogates the G1 cell cycle checkpoint and induces genomic instability, which plays a central role in cervical carcinogenesis. In this study, we observed that GCN5 was up-regulated in HPV E7-expressing cells, knockdown of GCN5 inhibited cell cycle progression and DNA synthesis in HPV E7-expressing cells. Notably, GCN5 knockdown reduced the steady-state levels of transcription factor E2F1. Depletion of E2F1 caused G1 arrest while overexpression of E2F1 rescued the inhibitory effects of GCN5 knockdown on G1/S progression in HPV E7-expressing cells. Results from chromatin immunoprecipitation (ChIP) assays demonstrated that GCN5 bound to the E2F1 promoter and increased the extent of histone acetylation within these regions. GCN5 also acetylated c-Myc and increased its ability to bind to the E2F1 promoter. Knockdown of c-Myc reduced the steady-state levels of E2F1 and caused G1 arrest. These results revealed a novel mechanism of E7 function whereby elevated GCN5 acetylates histones and c-Myc to regulate E2F1 expression and cell cycle progression.
key checkpoint to determine whether cells enter the S phase and proliferate. In normal case, cells arrest in G1 phase with DNA damage, which protects cells with damaged DNA from being replicating and allows the cellular repair systems to fix the damaged DNA.
HPV-16 E7 abrogates the G1 cell cycle checkpoint in part by degrading pRb, 6 resulting in the E2F transcription factor family member dissociation from pRb. Free E2Fs then bind to in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. 8 Acetylation, especially histone acetylation, plays a role in regulating gene expression. 9 Alteration of histone 3 and 4 acetylation level has been observed in a variety of cancers, including cervical cancer. 10, 11 Histone deacetylase 1 (HDAC1) and HDAC2 are up-regulated in cervical dysplasia and invasive cervical carcinoma. 12 In cervical cancer HeLa cells, down-regulation of HDAC2 expression inhibited cell proliferation and induced cell cycle arrest. 10 HPV E7
has been reported to modulate histone acetylation through several mechanisms. E7 was shown to associate with p300/CBP-associated factor (pCAF) and reduce its ability to acetylate histones. 13 Moreover, HPV E7 facilitated DNA replication by activating E2F2 transcription through its interaction with HDACs and inhibiting HDAC binding to the E2F2 promoter. 14,15 E7 proteins were found to bind to hypoxia-inducible factor 1 (HIF-1α) and enhance its transcription activities by inhibiting binding of HDACs. 16 E7 could directly target cdc25A transcription and maintains cdc25A gene expression by disrupting Rb/E2F/HDAC-1 repressor complexes during deregulation of cell cycle arrest. 17 Conversely, HPV E7 recruited HDACs to the promoter of interferon response factor 1 (IRF1) and suppressed its transcriptional activity. 18, 19 General control nondepressible 5 (GCN5), the first identified transcription-related lysine acetyltransferase (KAT), is an important catalytic component of a transcriptional regulatory complex. 20, 21 GCN5 plays a key role in a broad range of cellular functions, including cell proliferation, differentiation, telomere maintenance and DNA damage repair. [22] [23] [24] [25] As a key catalytic component of the larger SAGA and ATAC complexes, GCN5 preferentially acetylates lysines 9, 14, 27 and 56 of histone H3 and lysines 8 and 16 of H4. 20, 21, 26, 27 In recent years, GCN5 has also been implicated a function in certain oncogenic processes. In breast cancer cells, HBXIP (hepatitis B X-interacting protein) oncoprotein promotes the migration of breast cancer cells through modulating microtubule acetylation mediated by GCN5. 28 GCN5 is required for invariant natural killer T (iNKT)-cell development through EGR2 acetylation. 29 GCN5 positively regulates T-cell activation and loss of GCN5 functions impaired T-cell proliferation. 30 GCN5 promotes human hepatocellular carcinoma progression by enhancing de novo transcription of the AIB1 gene. 31 GCN5
increases the stability of c-Myc, one of the most frequently overexpressed genes in human cancer, 32, 33 by acetylating its K323 residue. 34 Moreover, GCN5 directly interacts with E2F1 and acetylates H3K9 on its promoter region to facilitate the expression of Cyclin E and Cyclin D1 to promote lung cancer cell proliferation and tumour growth. 22 The role of GCN5 in cervical cancer has not been reported yet.
In this study, we investigated the role of GCN5 in cell proliferation of HPV-16 E7-expressing cells and explored the mechanism by which GCN5 performs its functions. GCN5 was found to be up-regulated in HPV-16 E7-expressing cells. Down-regulation of the GCN5 reduced E7-induced G1 checkpoint abrogation. GCN5 mediated cell cycle proliferation by regulating E2F1 expression that was associated with increased acetylating histone 3 lysine 9 (H3K9) in the promoter of E2F1, overexpression of E2F1 rescued the inhibitory effect of GCN5 knockdown on G1/S transition. We also found that GCN5 regulated E2F1 expression by acetylating and stabilizing c-Myc, which bond and regulated E2F1 and promoted cell cycle proliferation.
| MATERIALS AND METHODS

| Cell culture
Spontaneously immortalized human foreskin keratinocytes (NIKS cells) were described previously 35 and cultured on mitomycin C-trea- Thirty-six hours after transfection, the cells were treated with DMSO or 10 μg/mL bleomycin and incubated for an additional 36 hours. Cells were harvested for protein knockdown analysis by
Western blotting or for cell cycle analysis by flow cytometry.
| Plasmids and transfection
The 
| Flow cytometry
For cell cycle experiment, cultured cells were treated with phosphate-buffered saline (PBS) or bleomycin (Alexis Biochemicals) (10 μg/mL in PBS). At 36 hours later, cells were fixed in 70% ethanol, treated with 50 μg/mL RNase A plus 50 μg/mL propidium iodide (PI).
The PI-stained cells were analysed by flow cytometry. Cell cycle analysis was performed using FlowJo software (Becton Dickinson). 
| Western blot
Total cellular proteins were extracted with radioimmunoprecipitation assay (RIPA) lysis buffer, and a Western blot assay was performed with specific antibodies against GCN5 (sc-55559, Santa Cruz), Cdk1 The bands of protein were detected using an Odyssey infrared imaging system (LI-COR, Lincoln, NE) and quantified using ImageJ (NIH).
| ChIP assay
The chromatin immunoprecipitation (ChIP) assay was performed using a ChIP assay kit from Millipore, following the manufacturers'
protocol. Immunoprecipitations were performed using anti-GCN5,
anti-c-Myc, anti-HA or control IgG antibodies. PCR was performed with the primers designed from the sequences of the human E2F1 gene as follows: forward 5′-AAGCCAATAGGAACCGCCG-3′, reverse 5′-AGTCCCGGCCACTTTTACG-3′ (for GCN5); forward 5′-TGAGGA TGGAAGAGGTGGCT-3′; reverse 5′-TTCTGCACGTGACCCTCAAC-3′
(for c-Myc or HA).
| Statistical analysis
Data are presented as means and standard deviations (SDs). The differences between means were evaluated using Student t test. P values of ≤ 0.05 were considered significant.
| RESULTS
| GCN5 expression was up-regulated in HPV-16
E7-expressing cells
E7 oncogene plays a key role in cervical carcinogenesis and abrogates the G1 checkpoint. 6 Our recent study showed that HPV-16 E7 abrogated the G1 checkpoint by up-regulating the Cdk1, Cdc6, WDHD1 and cancerous inhibitor of protein phosphatase 2A
(CIP2A), [37] [38] [39] [40] more detailed mechanisms remain to be elucidated.
Overexpression of GCN5 promotes cell growth and the G1/S phase transition. 22 We therefore speculated that GCN5 may play a role in E7-mediated cell cycle control. To test this, we firstly used HPV-16
E7-expressing NIKS cells (NIKS-E7)
. 41 NIKS cells exhibit many characteristics of early-passage human keratinocytes including stratification, differentiation and the ability to sustain the HPV life cycle 42, 43 and grow relatively well in culture. We found that the GCN5 mRNA level was up-regulated (~1.4-fold) in E7-expressing NIKS cells (Figure 1A) . As keratinocytes are difficult to achieve high transfection efficiencies in our experimental conditions, we also used RPE1 cells to express HPV-16 E7 (RPE1-E7). The RPE1 cells have been used in our recent HPV-related functional studies. 35, 36, 39 Similar to what was observed in keratinocytes, GCN5 mRNA levels were increased (~1.5-fold) in E7-expressing RPE1 cells ( Figure 1B) . Next, we examined the
steady-state level of GCN5 protein in E7-expressing cells. As shown in Figure 1C ,D, the levels of GCN5 protein were significantly upregulated in both RPE1-E7 cells (~1.8-fold) and NIKS-E7 cells (~5-fold). To directly demonstrate the ability of E7 to up-regulate GCN5, we transfected cells with plasmids encoding HPV-16 E7 and detected the expression of GCN5. As shown in Figure 1E , the steady-state level of GCN5 protein was increased upon E7 transfection. These results demonstrate that GCN5 expression was up-regulated in HPV-16 E7-expressing cells.
| GCN5 siRNA knockdown caused G1 arrest and inhibited DNA synthesis in HPV-16 E7-expressing cells
To test the potential role of GCN5 in E7-mediated cell cycle control, we used two independent siRNAs. The steady-state level of GCN5 protein was down-regulated (to 0.2-fold with siGCN5-1, to 0.5-fold with siGCN5-2) after transfection with siRNAs targeting GCN5 in RPE1-E7 cells ( Figure 2A ). Next, we examined the effect of GCN5 knockdown on cell cycle profiles in E7-expressing and vector-containing RPE1 cells. No significant effects on cell cycle profile were observed when regularly cultured RPE1 cells containing the vector or expressing E7 were treated with GCN5 siRNAs (data not shown).
To explore the role of GCN5 in G1 checkpoint, we treated cells with bleomycin (10 μg/mL), which causes both single-and double-strand DNA damage and induces normal cells to arrest at the G1 phase while cells expressing HPV E7 go through S phase and arrest at G2
phase, as we showed previously. 37 
| E2F1-dependent regulation of Cdk1 by GCN5 in E7-expressing cells
The progression of cell cycle is regulated by Cdks and cyclins at several checkpoints. Cdk2 is a major player for S phase entry, but its function can be compensated by Cdk1 in its absence, 44 as we demonstrated in E7-expressing cells. 37, 39 To explore the mechanism by which GCN5 regulates cell cycle, we detected the expression of genes involved in the G1 checkpoint, E2F1, Cdk1, Cyclin A, p53, pRb and Cdk4. The protein levels of E2F1, Cdk1, Cyclin A, p53 were up-regulated in E7-expressing cells ( Figure 3A ).
E2F1 has been generally considered as a positive regulator of transcription. 45 E2F1 binds in the upstream regions of the human Cdk1 and Cyclin A genes and accelerates their transcriptions. 46, 47 We transfected cells with siRNAs specific to GCN5 and found the protein levels of E2F1, Cdk1, Cyclin A and pRb were down-regulated ( Figure 3B ). Furthermore, the mRNA level of E2F1 was also downregulated with GCN5 knockdown ( Figure 3C ). As GCN5 positively regulated E2F1, 22 we believe it may do so as well in E7-expressing 45.5%) in E7-expressing cells ( Figure 4F ). Thus, E2F1 overexpression rescued the inhibitory effect of GCN5 knockdown on G1 arrest and Cdk1 and Cyclin A expressions in E7-expressing cells.
| GCN5 bond to the E2F1 promoter and increased histone H3 acetylation in E7 -expressing cells
As GCN5 is a histone acetyltransferase, it may acetylate histones in the cells, and we therefore examined histone 3 lysine 9 (H3K9) acetylation in E7-expressing cells. As shown in Figure 5A , the acetylated H3K9 was higher in E7-expressing cells, especially after treatment with histone deacetylase inhibitor trichostatin A (TSA). The acetylation level of H3K9 was decreased when cells were treated with siGCN5 ( Figure 5B ), indicating that GCN5 was responsible for the acetylation level of H3K9 in E7-expressing cells. As the expression of E2F1 was markedly regulated by GCN5 at both protein and mRNA levels in E7-expressing cells ( Figure 3B ,C) and GCN5 was shown to bind E2F1 promoter in lung cancer cell lines, 22 we believe that GCN5 binds E2F1 promoter in E7-expressing cells. To test this possibility, chromatin immunoprecipitation (ChIP) was used to evaluate the association of GCN5 on the E2F1 promoter. As shown in (Figure 5C ), the promoter region of E2F1 gene was significantly immunoprecipitated by the GCN5 antibody, indicating that endogenous GCN5 binds to the E2F1 promoters. To further establish the role of GCN5 in acetylating histones of E2F1 promoter, ChIP assay was performed to examine the acetylation level of H3K9 on chromatin by treating cells with siGCN5. As shown in Figure 5D , the acetylation level of H3K9 binding to the promoter of E2F1 was significantly decreased with GCN5 knockdown. These results indicate that GCN5 binds to and increases the histone H3 acetylation of the E2F1 promoter in E7-expressing cells. These results indicate that GCN5 regulates overall H3K9 acetylation as well as those on the E2F1 promoter. activate transcription partly relies on recruiting cofactor complexes including GCN5. 34 The c-Myc protein could be acetylated by GCN5/ PCAF, resulting in an increase in protein stability. 34 As the expression levels of both GCN5 and E2F1 were high in E7-expressing cells cells. 51 To confirm this in E7-expressing cells, we used ChIP assay.
As shown in Figure 7C , the promoter region of E2F1 gene was significantly immunoprecipitated with the c-Myc antibody. Significantly, the level of c-Myc binding to E2F1 promoters was significantly decreased when cells were treated with GCN5 siRNA (Figure 7D 
It was reported that GCN5 increases the stability and enhances transcription activation of c-Myc by acetylating its K323 residue. 34, 52 To test the possibility that K323 residue of c-Myc is important for acetylation and stability, we constructed c-Myc mutants with mutations at K323 (K323R, imitating the deacetylation status; K323Q, imitating the acetylation status). Consistent with previous observation that K323 acetylation affects c-Myc stability, the steady-state levels of K323R mutant of c-Myc were lower than that of the wild-type (Figure 7E) . What is important, the relative level of c-Myc binding to E2F1
promoters was also decreased for K323R ( Figure 7E) . However, the level of c-Myc binding to E2F1 promoters was not increased when transfected with plasmids encoding c-Myc (K323Q) that imitated the acetylation status of c-Myc (data not shown). It was reported that K323 overacetylation might cause reduced c-Myc protein stability while preserving stability in normal conditions. 53 This observation may explain why c-Myc was not always highly expressed in E7-expressing cells. 40 These results indicate that GCN5 could acetylate c-Myc, stabilize it, affect its level of binding to the E2F1 promoter, regulate E2F1 expression and modulate cell cycle progression.
| DISCUSSION
In this study, we investigated the mechanism underlying HPV-16 E7 abrogation of the G1/S cell cycle checkpoint. acetylating in the E2F1 promoter, and overexpression of E2F1 rescued the inhibitory effect of GCN5 knockdown on G1/S transition.
We also found that acetylation of c-Myc by GCN5 may contribute to E2F1 expression. Taken together, this study uncovered a novel function of GCN5 in high-risk HPV E7-mediated cell proliferation and has important implications in HPV-associated cancers.
GCN5 is a histone acetyltransferase (HAT) that plays key roles in a broad range of cellular functions, including transcription, 54 cell proliferation, 22 differentiation, 23 telomere maintenance 24 74 The expression of c-Myc correlated to HR-HPV (including HPV-16 and HPV-18)-infected epithelium compared with HR-HPVnegative epithelium. 75 An enhanced c-Myc level was also observed in cells expressing HPV E7. 76, 77 However, some reports showed no significant difference in the expression of c-Myc between vector and E7-expressing cells. 78 In this study, we did not find a significant increase in mRNA and protein level of c-Myc in HPV E7-expressing cells (data not shown), an observation consistent with our previous study. 40 Although we found that the steady-state levels of c-Myc Further studies are needed to explore detailed role of c-Myc acetylation by GCN5 to E2F1 regulation in HPV E7-expressing cells. In summary, our data suggest a model where HPV E7 up-regulates the expression of GCN5, which increases the expression of E2F1 through two pathways. In one case, GCN5 binds to the E2F1 promoter, increases histone H3 acetylation and promotes E2F1 transcription. In another case, GCN5 acetylates c-Myc, which promotes E2F1 transcription. As an E2F1 target, Cdk1 involves in G1/S progression. This GCN5/c-Myc/E2F1 pathway leads to abrogation of the G1 checkpoint in the presence of damaged DNA, genomic instability and contributing to HPV-induced carcinogenesis ( Figure S1 ).
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